Prognosis and Treatment of Necrotizing Soft Tissue Infections: A Prospective Cohort Study (ProTreat)

June 20, 2019 updated by: Ole Hyldegaard

ProTreat - Prognosis and Treatment of Necrotizing Soft Tissue Infections: A Prospective Cohort Study

The investigators will analyze biomarkers related to the prognosis and treatment of necrotizing soft tissue infections (NSTI). The focus will be on whether certain endothelial and immune system biomarkers can function as markers of disease severity, mortality as well as the effects of hyperbaric oxygen therapy (HBOT). Biomarkers will be measured upon admission to an intensive care unit at Copenhagen University Hospital and during the following 3 days.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

Introduction:

Necrotizing soft-tissue infections (NSTI) are among the most serious and deadly infections known. They are characterized by rapidly progressing soft-tissue inflammation with necrosis and can quickly cause multiple organ failure and death. Mortality has been shown to be 25-35 %, with survivors coping with amputations and prolonged rehabilitation.

Currently, there is a lack of proper tools to evaluate the severity and prognosis of NSTI in individual patients. This results in necessary, yet sometimes overzealous surgical debridement, culminating in prolonged patient rehabilitation and invalidity. Hyperbaric oxygen therapy (HBOT) may be added as adjunctive therapy of NSTI. However, there is no clear understanding of the effectiveness of HBOT on NSTI. The investigators seek to remedy these two issues by examining multiple biomarkers over the course of several studies.

Methodology:

Location: Copenhagen University Hospital, Rigshospitalet, Denmark.

Design: Observational cohort study.

Cohort: All NSTI patients in Denmark since 2013.

Controls: 50-100 Patients undergoing elective, orthopedic surgery at Rigshospitalet.

Biomarkers: soluble thrombomodulin, syndecan-1, sE-selectin, VE-cadherin, protein C, suPAR.

Sample size calculations:

1: The test kits the investigators will be using to measure the primary outcome sTM (Human sCD141 ELISA kit, Nordic Biosite) have an interassay standard variation of 0.58 ng/ml. In order to be certain that measured changes in sTM concentration are not a result of interassay standard deviation, the investigators have set the mimimum relevant difference in sTM to 3 x the interassay standard variation, thus 1.75 ng/ml.

The investigators prepared a power calculation using a Wilcoxon rank sum test. Assuming an estimated standard deviation of 4.6 ng/ml and a mean of 9.9 ng/ml, the investigators will need to include a maximum of 150 NSTI patients and 50 elective surgery patients to reach a statistical power of at the very least 60 % (a very conservative estimate) and presumably closer to 85 % (more realistic estimate) at a 5 % significance level. The estimates depend on data distribution.

2: The test kits the investigators will be using to measure the primary outcome sE-selectin (Human CD62E ELISA kit, Diaclone) have an interassay standard variation of 0.37 ng/ml. In order to be certain that measured changes in sE-selectin concentration are not a result of interassay standard variation, the investigators have set the mimimum relevant difference in sE-selectin to 3 x the interassay standard variation, thus 1.1 ng/ml.

Assuming an estimated standard deviation of 209 ng/ml (septic shock) vs. 23 ng/ml (severe sepsis and sepsis) and means of 295 vs. 181 ng/ml, respectively, the investigators will need to include at least 132 NSTI patients and 50 elective surgery patients to reach a statistical power of 90 % at a 5 % significance level.

3: suPAR levels during NSTI have never previously been examined. In order to estimate sample size and since NSTI patients are also septic, the investigators are basing the sample size calculation on a previous study concerning the correlation between suPAR and sepsis. This study found statistically significant correlation between suPAR levels and mortality in 141 patients. This is also the goal of this study. Further studies have also found significant correlations between suPAR, sepsis and mortality in 132 patients. The investigators will include at least 150 NSTI patients during this study.

Statistical considerations:

To check whether the HBOT treatment has an effect on the range of biomarkers, the investigators will analyze the means and variances of the biomarkers in the NSTI group and the two control groups, the orthopaedic patients and the sepsis patients. Non-parametric data will be log-transformed and will be presented as median values with IQR. Wilcoxon rank sum tests will be used for group comparisons. Fisher's exact test will be used for categorical data. Correlation analysis will be performed using Spearman rank correlation or Pearson correlation. To assess the quality of suPAR as a predictor of health outcomes, a model selection exercise will be conducted with various types of regression models. The type of regression will vary with the type of health-outcome, with suPAR as the predictor in all cases. Receiver operating characteristic (ROC) curve analysis will be applied to determine suPARs accuracy as a marker of severity and mortality in patients with NSTI. The investigators will construct Kaplan-Meier curves for survival data. Statistically significant results are when p<0.05.

Data:

Data will be handled according to the National Data Protection Agency. All original records (including consent forms and questionnaires) will be archived at the trial site for 15 years. The National Data Protection Agency has approved the biobank (RH-2016- 199). Data checks have been programmed into the data registry to warn when input variables are outside of predefined possible clinical range. All registry data will be compared to external data sources, i.e. medical records, to ensure accuracy. Standard Operating Procedures have been implemented regarding data collection. Patients with missing data for calculating for example SAPS II scores etc. will be excluded from the study.

Ethics:

The trial will adhere to the Helsinki Declaration and Danish law. The National Ethics Committee and the Regional Ethics Committee (H-16021845) have approved this study.

Biomarker analyses, data extraction and interpretation will be performed once the recruitment of participants has ended.

Study Type

Observational

Enrollment (Actual)

260

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Denmark
      • Copenhagen, Denmark, 2100
        • Copenhagen University Hospital, Rigshospitalet

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Probability Sample

Study Population

NSTI cohort:

All NSTI patients treated at the University Hospital of Copenhagen, Rigshospitalet.

Orthopaedic control cohort:

Undergoing elective orthopedic surgery (non-pathological fractures, joint replacement surgery or spine surgery) at Copenhagen University Hospital

Description

Inclusion criteria for NSTI patients (both of which must be met):

  • Diagnosed with NSTI based on surgical findings (necrosis of any soft tissue compartment; dermis, hypodermis, fascia or muscle)
  • Admitted to the Intensive Care Unit (ICU) and/or operated for NSTI at Copenhagen University Hospital

Exclusion Criteria for NSTI patients:

  • They are categorized as non NSTI in the operating theatre

Inclusion criteria for orthopaedic control patients:

  • Undergoing elective orthopedic surgery (non-pathological fractures, joint replacement surgery or spine surgery) at Copenhagen University Hospital

Exclusion criteria for orthopaedic control patients:

  • Ongoing infection or inflammatory condition

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Cohort
  • Time Perspectives: Prospective

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
NSTI patients
NSTI is an infection that requires acute hospitalization with intensive care treatment and/or surgery as a consequence of severe soft tissue infection in subcutis, muscle and/or fascia and that spreads along tissue structures.
Device: Hyperbaric oxygen therapy
Hyperbaric oxygen therapy with 100 % oxygen at 1.8 ATA for 2 hours.
Orthopaedic control patients
Elective orthopaedic control patients.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
sTM and sE-selectin as biomarkers of HBOT effect in NSTI patients
Time Frame: At admission, and during the next 3 days in the ICU
Changes in plasma sTM and sE-selectin concentrations in NSTI patients, compared with the control group
At admission, and during the next 3 days in the ICU
suPAR as a biomarker of disease severity and prognosis in NSTI patients with and without septic shock
Time Frame: At admission
Association between plasma suPAR levels and NSTI mortality, and SAPS II and SOFA scores
At admission

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Amputation rate
Time Frame: During ICU admission (expected average of 8 days)
At any anatomical site
During ICU admission (expected average of 8 days)
Microbial etiology
Time Frame: During ICU admission (expected average of 8 days)
Tissue and blood samples
During ICU admission (expected average of 8 days)
Time from admission to primary hospital until first surgery/debridement
Time Frame: 2 days
2 days
Mortality
Time Frame: While in the ICU, and at 28, 90, 180 days
Mortality
While in the ICU, and at 28, 90, 180 days
ICU scoring systems
Time Frame: During ICU admission (expected average of 8 days)
SAPS II (day 1) APACHE II (day 1) SOFA, GCS excluded (day 1-7)
During ICU admission (expected average of 8 days)
Multiple organ failure
Time Frame: During ICU admission (expected average of 8 days)
Multiple organ failure
During ICU admission (expected average of 8 days)
Debridements
Time Frame: During ICU admission (expected average of 8 days)
Number of debridements
During ICU admission (expected average of 8 days)
Ventilator treatment
Time Frame: During ICU admission (expected average of 8 days)
Ventilator treatment during stay at ICU
During ICU admission (expected average of 8 days)
Renal replacement therapy
Time Frame: During ICU admission (expected average of 8 days)
Renal replacement therapy during stay at ICU
During ICU admission (expected average of 8 days)
Vasopressor treatment
Time Frame: During ICU admission (expected average of 8 days)
Vasopressor treatment during stay at ICU
During ICU admission (expected average of 8 days)
Steroid treatment
Time Frame: Up to 7 days before surgical diagnose at primary hospital
Steroid treatment (injection/oral intake) up to development of NSTI
Up to 7 days before surgical diagnose at primary hospital
HBOT and endothelial biomarkers
Time Frame: At admission, and the next 3 days in the ICU
Any differences in sTM, syndecan-1, sE-selectin, VE-cadherin and protein C levels between NSTI patients who do not receive HBOT within the first 24 hours of ICU admission (because they are deemed too unstable for HBOT) vs. those who receive HBOT within the first 12 and 24 hours of ICU admission
At admission, and the next 3 days in the ICU
Biomarkers and disease severity
Time Frame: At admission, and the next 3 days in the ICU
Systemic inflammatory response syndrome, sepsis, severe sepsis and septic shock will be diagnosed according to standardized criteria (American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference Committee) and suPAR, sTM and sE-selectin will be investigated to see if there is a correlation between disease severity in these groups
At admission, and the next 3 days in the ICU

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Ole Hyldegaard

Collaborators

Seventh Framework Programme

Investigators

  • Study Director: Ole Hyldegaard, MD, PhD, Rigshospitalet, Denmark
  • Principal Investigator: Peter V Polzik, MD, Rigshospitalet, Denmark

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

February 1, 2013

Primary Completion (Actual)

January 1, 2018

Study Completion (Actual)

January 1, 2018

Study Registration Dates

First Submitted

April 26, 2017

First Submitted That Met QC Criteria

May 6, 2017

First Posted (Actual)

May 10, 2017

Study Record Updates

Last Update Posted (Actual)

June 24, 2019

Last Update Submitted That Met QC Criteria

June 20, 2019

Last Verified

June 1, 2019

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • PROTREAT1-PP-2017

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

No

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Fournier Gangrene

Clinical Trials on Hyperbaric oxygen therapy

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Nigeria

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe